Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
In high-risk people with type 2 diabetes, the degree of liver fibrosis, as estimated by FIB-4 score, was not related to incident cardiovascular outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of FIB-4 category.
Authors
- Kelley R. Branch (ORCID: https://orcid.org/0000-0003-2362-6498)
- Zhuoru Li (ORCID: https://orcid.org/0000-0001-8992-6616)
- Stefano Del Prato (ORCID: https://orcid.org/0000-0002-5388-0270)
- Hertzel C. Gerstein (ORCID: https://orcid.org/0000-0001-8072-2836)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Richard E. Pratley (ORCID: https://orcid.org/0000-0002-2912-1389)
- Renato D. Lópes (ORCID: https://orcid.org/0000-0003-2999-4961)
- Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
- Chinthanie Ramasundarahettige (ORCID: https://orcid.org/0009-0004-3705-8879)
- N Sattar
Institutions
- Scuola Superiore Sant'Anna (IT)
- National University of Singapore (SG)
- University of Washington (US)
- Population Health Research Institute (CA)
- Clinical Research Institute (US)
- National University Heart Centre Singapore (SG)
- Duke Medical Center (US)
- Translational Research Institute for Metabolism and Diabetes (US)
- Velocity Clinical Research (United States) (US)
- National Heart Centre Singapore (SG)
- Hamilton Health Sciences (CA)
- University of Glasgow (GB)
- McMaster University (CA)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s12933-024-02432-7
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Sanofi